INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical corporation (OTCQB:INTI) specializing in the development and commercialization of advanced therapies for patients with cancer as well as non-malignant proliferation disorders. The company's primary product candidate, SUBATM-Itraconazole, is an oral formulation of the well-known anti-fungal drug itraconazole, patented and studied for its activity against various tumor types when used to treat cancer patients. INHIBITOR is specifically focusing on the development of SUBA-Itraconazole for advanced, metastatic castrate-resistant prostate cancer (mCRPC).
Inhibitor Therapeutics
Headquarters
United States of America